Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | NEK2 | P51955 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27494524 | 0.79 | NPC1 (0.44) | CHRNB2CHRNA7CHRNA4NEK2 | |
| SCHEMBL5833130 | 0.79 | ALDH1A1 (0.49) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL5832239 | 0.78 | CHRNA7 (0.57) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL925343 | 0.78 | CHRNB2 (0.67) | HRH4CYP11B1CYP11B2CHRNB2CHRNA7 | |
| SCHEMBL3387347 | 0.75 | CHRNA7 (0.45) | HRH4CHRNA7HTR6 | |
| SCHEMBL5832709 | 0.75 | CHRNB2 (0.41) | CYP11B2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL5833150 | 0.74 | HRH4 (0.38) | HRH4HTR6P2RX3 | |
| SCHEMBL6210726 | 0.74 | CHRNB2 (0.40) | CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL5041409 | 0.74 | CHRNB2 (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL5832405 | 0.74 | CHRNB2 (0.49) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | disclosed |
| EP-1301514-B1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2005-01-26 | — | — | EP | disclosed |
| CN-1185233-C | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2005-01-19 | — | — | CN | disclosed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| CN-1440411-A | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH AS (DK) | 2003-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | CHRNA7, CHRNA5, CHRNA2 | HRH4 309/4885CYP11B1 529/4885CYP11B2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.